The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 11, 2023. Its latest SEC filing is a 15-12G from Jun 20, 2023.
10-Q for Q1 FY2023, filed May 11, 2023
The sections below describe the company as of the FY2022 annual report.
Develops a dry-powder nasal drug-device treatment for acute migraine for people with migraine.
10-K for FY2022, filed Mar 28, 2023
No revenue was reported.
10-K for FY2022, filed Mar 28, 2023
10-Q for Q1 FY2023, filed May 11, 2023
−$10.3MView ↗
8-K, filed Jun 8, 2023
On June 8, 2023, following consummation of the Offer, Purchaser merged with and into the Company, with the Company surviving the merger as…View ↗
8-K, filed Apr 17, 2023
Under the terms of the definitive agreement, which has been approved by the boards of directors of both SNBL and Satsuma, SNBL will…View ↗
Commercialization strategy
Earlier, the company planned to develop the drug through approval, build a domestic sales team, and seek partners in other markets; the later plan is to find a partner to fund continued development and commercialization while limiting spending.
10-K for FY2019, filed Mar 10, 2020 10-K for FY2022, filed Mar 28, 2023Our strategy is to develop and commercialize STS101 and address the significant unmet medical needs of a large number of people with…View ↗
Advance STS101 through clinical development and regulatory approval for the acute treatment of migraine. In July 2019, we initiated our…View ↗
Commercialize STS101 in the United States. If approved, we plan to commercialize STS101 in the United States by building a specialized…View ↗
Pursue market opportunities for STS101 outside the United States with one or more partners. We believe there is a significant market…View ↗
Competes with Bausch Health, Impel NeuroPharma, Eli Lilly, Abbvie, and Pfizer
10-K for FY2022, filed Mar 28, 2023In 2022, approximately 19.3 million prescriptions for migraine-specific acute therapies were written in the United States. This figure…View ↗
Loading...
